We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00615940
Recruitment Status : Completed
First Posted : February 14, 2008
Last Update Posted : February 28, 2014
U.S. Army Medical Research and Development Command
Information provided by (Responsible Party):
Heidelberg Pharma AG

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 2011
Actual Study Completion Date : April 2012
Certification/Extension First Submitted : January 28, 2014